5mg / vial
D-Lys-GHRP6 or Ghrelex is an ghrelin antagonist, meaning it is a peptide with opposite effects of ghrelin. When D-Lys-GHRP6 is administered in mammals, it has the effect of inhibiting the effects of ghrelin within the body. Ghrelin is secreted mainly from the human stomach and pancreas and is the first identified circulating hunger hormone. In other words, ghrelin affects the brain chemistry and induces hunger but is not produced solely in the brain. When it is produced in the brain, it causes growth-hormone release from the anterior pituitary. Administering D-Lys-GHRP6 would be unlikely to inhibit growth-hormone release unless the peptide was incidentally administered during a natural growth-hormone release pulse. D-Lys-GHRP6 does hold some potential for hunger suppression in obese individuals.
Ghrelin can act as an insulin secretagogue in “glucose-stimulated conditions.” Insulin blunts lipolysis and prevents fat oxidation, and overseretion of insulin during consumption and metabolism of glucose is a symptom of the pre-diabetic condition. It is possible that as a part of planned reduction in consumption of carbohydrates and glucose, inhibition of ghrelin’s actions via D-Lys-GHRP6 could result in decreased adiposity over time.
Because ghrelin has been implicated in the spread of gastrointestinal and pancreatic malignancy, it stands to reason that inhibition of ghrelin via D-Lys-GHRP6 could slow the spread of such cancers.
In thinner and leaner people, ghrelin levels follow a circadian cycle and increase from midnight to dawn. In obese people this rhythm appears to be disrupted. Lack of sleep also leads to altered ghrelin production and induces greater appetite, meaning that insomnia and disrupted sleep patterns are risk factors for obesity. D-Lys-GHRP6 may hold potential to either partially restore these disruptions in rhythm or at least mitigate negative outcomes.
Inui A, Asakawa A, Bowers CY, et al. (2004). "Ghrelin, appetite, and gastric motility: the emerging role of the stomach as an endocrine organ". FASEB J. 18 (3): 439–56.
Gauna C, Kiewiet RM, Janssen JA, van de Zande B, Delhanty PJ, Ghigo E, Hofland LJ, Themmen AP, van der Lely AJ. Unacylated ghrelin acts as a potent insulin secretagogue in glucose-stimulated conditions. Am J Physiol Endocrinol Metab. 2007 Sep;293(3):E697-704.
Waseem T (March 2009). "Commentary: Ghrelin's role in gastrointestinal tract cancer". Surg Oncol 19 (1): e1.
Yildiz B, Suchard M, Wong M, McCann S, Licinio J (2004). "Alterations in the dynamics of circulating ghrelin, adiponectin, and leptin in human obesity". Proc Natl Acad Sci USA 101 (28): 10434–9. doi:10.1073/pnas.0403465101. PMID 15231997. PMC 478601. http://www.pnas.org/cgi/pmidlookup?view=long&pmid=15231997.
*The latter article is intended for educational / informational purposes only. THIS PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. Bodily introduction of any kind into humans or animals is strictly forbidden by law.